Please login to the form below

Not currently logged in
Email:
Password:

Tiziana Life Sciences appoints clinical sciences VP

Dr Robert Evans joins the UK biotechnology firm

London-based Tiziana Life Sciences has appointed Dr Robert Evans as its new vice president of clinical sciences.

Dr Evans joins the clinical stage biotechnology company from Glenmark Pharmaceuticals, where he also served as vice president of clinical sciences.

In that role, he was responsible for providing project and clinical leadership across multiple programmes focused on the treatment of oncology, respiratory and dermatology disorders.

Prior to this, Dr Evans held a number of scientific leadership positions while at Amgen, Johnson & Johnson and Regeneron.

James Tripp, chief operating officer at Tiziana Life Sciences, said: “Bob's extensive background in the clinical development industry… combined with his strong background in immunology and oncology adds tremendous support to our exciting portfolio.

“I am very confident that together with out impressive pipeline and strong team we will continue to drive the company forward to significant future success.”

6th May 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics